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g.2014.0Abstract Background: Recurrent urinary tract infection (UTI) is common among young women
and one of its risk factors is genetic. Polymorphisms in promoter region (G-800A (rs1800468) and
C-509T (rs1800469)) of transforming growth factor-b1 (TGF-b1) gene play pivotal roles in several
infection diseases but the association of these polymorphisms with recurrent UTI remains unclear.
The aim of this study was to assess the correlation of TGF-b1 G-800A and C-509T polymorphisms
with recurrent UTI in young women.
Subjects and methods: TGF-b1 G-800A and C-509T polymorphisms among 34 recurrent UTI
patients and 34 healthy subjects, aged 15–50 years old, were evaluated with polymerase chain reac-
tion-restriction fragment length polymorphism (PCR-RFLP) and conﬁrmed by DNA sequencing.
Results: At position 800, genotypes showed no signiﬁcant differences between recurrent UTI
patients (GG 97.1%; GA 2.9%; AA 0%) and normal control (GG 97%; GA 0%; AA 2.9%) youngt of Internal Medicine, School
y, Banda Aceh, Indonesia.
(M. Syukri).
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126 M. Syukri et al.women. Dominant and recessive model analyses did not ﬁnd signiﬁcant correlation between recur-
rent UTI patients and normal control young women. At position 509, allelic and genotypic fre-
quencies showed no signiﬁcant differences between recurrent UTI patients (CC 20.6%; CT
61.8%; TT 17.7%) and control individuals (CC 2.9%; CT 73.6%; TT 23.5%).
Conclusion: This study found that there is no strong correlation between polymorphisms of
TGF-b1 G-800A and C-509T and recurrent UTI.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Recurrent urinary tract infection (UTI) is an episode of UTI
which is at least two times in six months or three or more
re-infections with clinical symptoms of UTI in a year. It is
common among young women even with normal urinary tract
health. Recurrent UTI is one of the main causes of renal scars,
increased renal insufﬁciency and hypertension, and contributes
to high morbidity and increased health care costs [1]. Some
hypotheses suggest that recurrent UTI is related with host fac-
tors and behavioral risk factors [1,2]. Previous studies found
that sexual activity, use of contraception (diaphragm and sper-
micidal), antibiotics, estrogen, a short anatomical distance be-
tween the urethra and anus, and genetic factors were
correlated with recurrent UTI [3,4].
Transforming growth factor-b1 (TGF-b1) is a key cytokine
that initiates and terminates tissue repair. TGF-b1 is the major
ﬁbrogenic growth factor implicated in the pathogenesis of re-
nal scarring [5] and a key mediator of glomerular and tubu-
lo-interstitial pathobiology in chronic kidney diseases [6].
Previous studies have found that TGF-b1 plays a pivotal role
in pathogenesis of ﬁbrosis in human kidney [7,8] and glomer-
ular disease [7].
TGF-b1 gene, which is located on chromosome 19q13 and
encoded by seven exons [9], has been implicated as a candidate
gene in the pathomechanism of numerous kidney diseases.
Since TGF-b1 acts as a proinﬂammatory or anti-inﬂammatory
cytokine depending on its concentration, polymorphisms
which alter TGF-b1 production are implicated in numerous
diseases [10–15]. Several polymorphisms have been found in
the TGF-b1 gene, C-988A, G-800A, C-509T, G-25C, T-10C,
G915C, T869C and C788T [10,14,16], and two of the most
studied intensively are G-800A and C-509T which are localized
in the promoter region. A case-control study reported that
TGF-b1 G800A and C-509T polymorphisms are related to re-
nal parenchymal scarring in childhood UTI [11]. Another case-
control study found an increase in TGF-b1–800GG and –
509CC genotypes among childhood UTI and vesicoureteral re-
ﬂux (VUR) [12]. However, the role of these polymorphisms in
recurrent UTI among young women is still unknown. This
study aimed to determine the correlation between TGF-b1
G-800A and C-509T polymorphisms and recurrent UTI
among young women.
2. Subjects and methods
2.1. Subjects
Thirty-four young women, aged 15–50 years old, with recur-
rent UTI which conﬁrmed with clinical manifestation and ur-
ine culture and 34 normal young women were included in thisstudy. Recurrent UTI criteria based on Society of Obstetri-
cians and Gynecologists of Canada [17] and European Associ-
ation of Urology [18] were applied in this study. Normal
woman was deﬁned as person with no clinical symptom of
UTI in the last three years with no sign and symptom of infec-
tion at the enrollment time of this study. Patients post meno-
pause, post manipulated bladder, diabetes mellitus, liver
cirrhosis, immunosuppressive diseases, use of immunosuppres-
sive drug, and kidney transplant were excluded from the study.
This study was conducted with the approval of the Ethics
Committee of School of Medicine, Syiah Kuala University,
Banda Aceh, Indonesia, No. 066/KI/FK/201. The subject
recruitment and sample collection were done only after obtain-
ing written informed consent of the participants. The work is
carried out in accordance with The Code of the World Medical
Association (Declaration of Helsinki) for experiments involv-
ing humans.2.2. DNA extraction and TGF-b1 genotyping
DNA isolation was carried out in Molecular Biology Labora-
tory, School of Medicine, Syiah Kuala University, Banda
Aceh, Indonesia; PCR-RFLP was conducted in Faculty of
Medicine, Gadjah Mada University, Yogyakarta, Indonesia
and DNA sequencing conﬁrmation was conducted in 1st
BASE Pte Ltd Laboratory Singapore. Brieﬂy, 2.5 ml periphe-
ral venous blood was obtained from recurrent UTI young wo-
men cases and healthy woman, then DNA was extracted from
whole blood as described previously [19]. Genotyping was car-
ried out as described in previous report [12]. PCR ampliﬁca-
tion for each TGF-b1 G-800A and C-509T polymorphism
was performed in a total reaction volume of 20 lL with 2 lL
of genomic DNA, 5 lL of each of primer, 250 lM dNTP,
40 mM KCl, 1.5 mM MgCl2, 10 1 U TaqDNA polymerase
and 10 mM Tris–HCl (pH 9.0) (Pharmasia). PCR conditions
included denaturation at 94 C for 5 min, followed by 32 or
35 cycles at 94 C for 1 min, annealing at 57.5–62 C for 30–
40 s, extension at 72 C for 1 min, and ﬁnal extension at
72 C for 5 min.
For the G-800A polymorphism, 50-ACAGTTGGCACGG
GCTTTCG-30 was used as forward primer and 50-TCAACAC
CCTGCGACCCCAT-30 was used as reverse primer. For the
C-509T polymorphism, 50-CCCGGCTCCATTTCCAGGTG-
30 was used as forward primer and 50-GGTCACCAGAG
AAAGAGGAC-30 was used as reverse primer. Restriction
fragment length polymorphism (RFLP) was performed by
digestion of 10 lL of PCR product with 10 lL of restriction
enzyme for 1 h. For C-509T polymorphism, the PCR products,
808 bp in length, were digested with Bsu36I and for G-800A
polymorphism, the PCR products, 388 bp in length, were di-
gested with MaeIII. Digested products were electrophoresed
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ampliﬁed products, three samples from each group, were con-
ﬁrmed by DNA sequencing, using an ABI PRISM BigDye
Terminator Cycle Sequencing Ready Reaction Kit and a
3730 DNA analyzer (Applied Biosystems).
2.3. Statistical analysis
Differences in the genotype, dominant and recessive model,
and allele frequencies between recurrent UTI cases and con-
trols were analyzed with Chi-square test to assess the risk of
TGF-b1 G-800A and C-509T polymorphisms with recurrent
UTI. Genotype data were compared using 2 · 3 contingency
table of Chi-square test, dominant and recessive model, and al-
lele data compared using 2 · 2 contingency table of Fisher’s
exact test using statistical computational tools available at
http://www.vassarstats.net. Two sided testing was used for
all signiﬁcant comparisons to evaluate statistically a p-value
of 60.05 as signiﬁcant. Risk factors and recurrent UTI corre-
lations were analyzed with Chi-square test and Fisher’s exact
test or t-test as appropriate with data.
3. Results
3.1. Sample characteristic and risk factors
A total of 68 young women participants, (34 patients with
recurrent UTI, mean age was 32 years old; 34 healthy women
as control, mean age was 26.1 years old) were enrolled in this
study. Several risk factors of recurrent UTI are presented in
Table 1. Age, sexual intercourse frequency (per week), marital
status and intrauterine device contraception were signiﬁcantly
correlated with recurrent UTI.
3.2. Polymorphism of TGF-b1 G-800A and C-509T
The location of G-800A and C-509T polymorphisms in the
TGF-b1 promoter (modiﬁed from [20]), and the electrophore-
sis results of PCR-RFLP are shown in Fig. 1. For the G-800A
polymorphism genotyping, the PCR products, 388 bp in
length, were digested with MaeIII. Two fragments of 205
and 183 bp are categorized as homozygous GG genotype,
whereas a 388 bp fragment was categorized as homozygous
AA genotype. Three fragments of 388, 205 and 183 bp were
categorized as heterozygous GA (Fig. 1B). For the C-509TTable 1 Risk factors of recurrent UTI.
Risk factors Sub
R-U
Married* Yes 29
No 5
Intrauterine device* Yes 7
No 27
Age (years) 32
Sexual intercourse frequency (per week) 1.9
R-UTI, recurrent urinary tract infection; OR, odd ratio. 95% CI, 95 con
* Analyzed with Chi-square or Fisher’s exact test.
 Analyzed with t-test.polymorphism genotyping, the ampliﬁed 808 bp fragments
were digested with Bsu36I. Two fragments of 617 and 191 bp
were shown if the product was digestible and categorized as
homozygous CC genotype (cuttable), whereas 808 bp fragment
was categorized as homozygous TT genotype (uncuttable).
Three fragments of 808, 617 and 191 bp were categorized as
the heterozygous CT genotype (Fig. 1C).
In this study, 97.1% (33 of 34 subjects in both the recurrent
UTI and control groups) were homozygous GG at G-800A.
Only a single subject with recurrent UTI (2.9%) had the het-
erozygous GA genotype. Only one of the normal subjects
was found to have the homozygous genotype AA (Table 2).
There was no statistically signiﬁcant difference in G-800A
genotype or allele frequencies between recurrent UTI young
women and controls. Evaluation of C-509T genotypes indi-
cated that 7 (20.6%) of recurrent UTI and 1 (2.9%) of normal
subjects, have the CC genotype. In addition, 21 (61.8%) of the
recurrent UTI and 27 (73.6%) of normal subjects were the het-
erozygous CT genotype. The TT genotype was found in 6
(17.7%) of recurrent UTI cases and 8 (23.5%) of normal sub-
jects (Table 2). After adjustment, there was no statistically sig-
niﬁcant difference in C-509T genotype or allele frequency
distributions between recurrent UTI young women and con-
trols; however, there is a signiﬁcant association between recur-
rent UTI in young women and the C-509T locus C allele when
considering a genetic dominance model.
4. Discussion
There are several risk factors of recurrent UTI such as frequent
sexual intercourse, use of contraception (intrauterine device
contraception, diaphragm and spermicidal), use of antibiotics,
UTI history, and mother with UTI history, estrogen levels,
and anal and urethra anatomy [2,3,21–23]. Our results support
previous ﬁndings of sexual intercourse frequency, marital sta-
tus and intrauterine device contraception that were correlated
with recurrent UTI.
Besides those risk factors, various studies have been con-
ducted to investigate genetic factors of recurrent UTI suscepti-
bility in humans. A review study found that several genes in
humans such as CXCR1, CXCR1, TLR2, TLR4, HSPA1B
and TGF-b1 were associated with susceptibility to recurrent
UTI [13]. The role of TGF-b1 in recurrent UTI has not been
studied. TGF-b1 is an important immunoregulatory cytokine,
it controls cell proliferation, synthesizes extracellular matrix,
and plays a pivotal role in cellular immunity response. Itjects OR (95% CI) p
TI Control
10 13.9 (4.2–46.3) 0.000
24
1 8.6 (0.9–73.9) 0.027
33
26.1 0.000
0.62 0.000
ﬁdence interval.
Figure 1 Location of G-800A and C-509T polymorphisms in the TGF-b1 promoter and electrophoresis pattern of polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP) of these polymorphisms. (A) Diagrammatic representation of the
putative transcription factor binding sites in the TGF-b1 promoter and restriction site of MaeIII and Bsu36I (modiﬁed from [20]). (B and
C) Electrophoresis pattern of PCR-RFLP G-800A and C-509T polymorphisms. Green boxes are sp1 transcription factor binding sites;
vertical red lines are activating protein 2 (ap2) transcription factor binding site; brown ovals are nuclear hormone binding element; purple
box is cAMP response element-binding (CREB) half-site.
Table 2 Distribution of allelic and genotypic of the TGF-b1 in recurrent UTI (N= 34) and control groups (N= 34).
TGF-b1 genotype and allele R-UTI N (%) Control N (%) p OR (95% CI)
Genotype: C-509T
CC 7 (20.6) 1 (2.9)
CT 21 (61.8) 25 (73.6)
TT 6 (17.7) 8 (23.5) 0.077
Dominant model
CC 7 (20.6) 1 (2.9)
CT + TT 27 (79.4) 33 (97.1) 0.054 0.12 (0.01–1.01)
Recessive model
CC+ CT 28 (82.4) 26 (76.5)
TT 6 (17.6) 8 (23.5) 0.765 0.69 (0.21–2.28)
Allele
C 35 (51.5) 27 (39.7)
T 33 (48.5) 41 (60.3) 0.220 0.62 (0.31–1.22)
Genotype: G-800A
GG 33 (97.1) 33 (97.1)
GA 1 (2.9) 0 (0.0)
AA 0 (0) 1 (2.9) 0.368 -
Dominant model
GG 33 (97.1) 33 (97.1)
GA+ AA 1 (2.9) 1 (2.9) 1.000 1 (0.06–16.66)
Recessive model
GG+GA 34 (100) 33 (97.1)
AA 0 (0.0) 1 (2.9) 0.999 0 (0-NaN)
Allele
G 67 (98.5) 66 (97.1)
A 1 (1.5) 2 (2.9) 0.999 0.49 (0.04–5.56)
R-UTI, recurrent urinary tract infection; OR, odd ratio. 95% CI, 95 conﬁdence interval.
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Polymorphisms of transforming growth factor-b1 gene 129inhibits proliferation of T and B cells, antagonizes proinﬂam-
matory cytokines (TNF-a and IFN-c), blocks cytotoxic T lym-
phocyte activity and inhibits induction of receptors for IL-1
and IL-2, inhibits adhesion of T cells and neutrophils to endo-
thelial cells, inhibits activation of macrophages and down reg-
ulates MHC class II expression on macrophages [24]. Because
of these activities, a number of reports found that TGF-b1 has
multiple roles to play in the pathogenesis of several infectious
diseases (both non-urinary tract infection and urinary tract
infection) and immunologic diseases [11–15,25–32]. TGF-b1
polymorphism is correlated with UTI in children and vesicou-
reteral reﬂux [11,12], dengue infection [10], hepatitis C infec-
tion [13], and the development of chronic periodontitis [14].
The level of TGF-b1 is correlated with HIV infection [25], hep-
atitis B infection [26], inﬂuenza A H1N1 [27] and some para-
sitic infections such as Trypanosoma cruzi [28] and
Plasmodium yoelii [29]. In addition, TGF-b1 is also associated
with immunologic diseases such as systemic sclerosis [30], rheu-
matoid arthritis [31], and psoriasis vulgaris [32]. Previous re-
search aimed to measure the TGF-b1 level in urine as a
response marker towards immunosuppressive treatment in
crescentic nephritis found that TGF-b1 concentration in urine
was elevated signiﬁcantly in patients without improving kidney
function with immunosuppressive treatment [33]. A couple of
studies implicated that TGF-b1 plays a pivotal role in congen-
ital obstructive uropathy pathogenesis and acute pyelonephri-
tis [12,34]. A case control study in pediatric patient with
chronic kidney disease reported that TGF-b1 excretion was
higher compared with TGF-b1 levels in healthy children [34].
TGF-b1 also has a pivotal role in glomerular ﬁltration barrier
loss and proteinuria [35]. TGF-b1 is involved in extracellular
matrix accumulation, ﬁbrosis, renal impairment progression,
changes to the glomerular ﬁltration barrier, induction of pro-
teinuria [35], associated with IgA nephropathy and thin glo-
merular basement membrane disease [36]. TGF-b1
overexpression has caused proteinuria in animal models [37]
and inhibition of TGF-b1 reduces proteinuria [38].
Nine polymorphisms have been identiﬁed in the TGF-b1
gene: three reside in the promoter region, C-988A, G-800A,
C-509T, an insertion (C) in the 50UTR at position +72, two
polymorphisms are in the signal sequence, one in exon 5 and
one in each of introns 4 and 5 [39]. G-800A polymorphism is
in a consensus cAMP response element-binding (CREB)
half-site and the A allele would be expected to have reduced
afﬁnity for the CREB family of transcription factors, conse-
quently contributing to a lower production of total TGF-b1
in the circulation [20,40]. In addition, the 509T allele had
previously been associated with higher serum concentration
of TGF-b1 [38]. The association of TGF-b1 G-800A and C-
509T polymorphisms with several diseases related to urinary
tract infection has been investigated in a couple of studies
[11,12]. A case-control study reported that TGF-b1 G-800A
and C-509T polymorphisms were linked to kidney parenchy-
mal scarring in childhood after UTI [11]. TGF-b1 genotypes
were associated with an alteration of the host response to
UTI in children [12]. Yim et al. [12] found that an increased
509CC and 800GG genotype frequency and decreased
509TT and 800GA genotype frequency were related to
UTI.
Recurrent UTI may result from defect of local defense. This
might be explained by opsonizing antibody weakness, which
leaves the urinary tract mucous unable to neutralize microbialinvasion. This explanation is supported with the unique blad-
ders mucous because of opsonizing antibody weakness im-
pacts; therefore, urinary tract mucous become unable to
neutralize the microorganisms invasion. Other factors, such
as weakening of host immunity, also lead to recurrent UTI
[1]. Because TGF-b1 has important roles in human immunity
system, as mentioned before, various studies found that
TGF-b1 polymorphisms were associated with several infec-
tious [10,13,14] and immunologic diseases [30–32]. All of those
data reveal that TGF-b1 has a pivotal role in infection and
immunologic-diseases. However, this study found there was
no signiﬁcant association between TGF-b1G-800A and T-
509C polymorphisms and recurrent UTI. Yim et al. [12] also
state that it is difﬁcult to determine whether the TGF-b1 poly-
morphisms correlate with risk of UTI.
There are some limitations of this study. First, the sample
size of the phenotype groups was relatively small. Second, ser-
um TGF-b1 concentrations or gene expression of TGF-b1 in
peripheral blood mononuclear cells were not measured. The
TGF-b1 concentrations are important because although sev-
eral studies found that G-800 and T-509 alleles are associated
with serum or in vitro TGF-b1 level; contrasting results have
been published [11,20,41]. Therefore, further study comparing
TGF-b1 gene polymorphisms, measuring transcription and
TGF-b1 concentrations in serum with large sample size is re-
quired to investigate the potential roles of TGF-b1 on recur-
rent UTI.
5. Conclusion
In conclusion, there was no strong association between two
TGF-b1 genetic variants’ promoter region (positions: 800
and 509) with recurrent UTI among young women.
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